Quality of life in patients randomized to receive a bone marrow or a peripheral blood allograft

dc.creatorDe Souza, CA
dc.creatorDuraes, MIC
dc.creatorVigorito, AC
dc.creatorAranha, FJP
dc.creatorOliveria, GB
dc.creatorEid, KAD
dc.creatorZulli, R
dc.creatorMiranda, ECM
dc.creatorBotega, NJ
dc.date2002
dc.dateDEC
dc.date2014-11-17T22:49:49Z
dc.date2015-11-26T17:43:02Z
dc.date2014-11-17T22:49:49Z
dc.date2015-11-26T17:43:02Z
dc.date.accessioned2018-03-29T00:25:02Z
dc.date.available2018-03-29T00:25:02Z
dc.identifierHaematologica. Ferrata Storti Foundation, v. 87, n. 12, n. 1281, n. 1285, 2002.
dc.identifier0390-6078
dc.identifierWOS:000179836800011
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/58567
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/58567
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/58567
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1287472
dc.descriptionBackground and Objectives. Quality of life (QOL) is an important clinical end-point to be considered in the late follow-up of patients treated with allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation. Design and Methods. To assess the QOL in a group of survivors of hematologic malignancies who had been enrolled in a prospective randomized trial comparing allogeneic BM with PBPC. Sixty randomized patients had been enrolled in a study comparing BM-with PBPC graft during 1995-99. At the time of this QOL study, 30 were alive and 26 (13 BM and 13 PBPC) were eligible. Clinical and demographic data were collected and psychometric instruments (WHOQOL-100 and the Hospital Anxiety and Depression Scale-HAD) were used. Non-parametric and univariate analyses were performed. Results. The PBPC recipients had more chronic graft-versus-host disease (p=0.03) and were on immunosuppressive treatment for a longer period (p=0.02). The WHOQOL-100 analysis demonstrated significant differences between groups With, more favorable results in the BM group in the facets of Pain and Discomfort (p=0.03), Mobility (p=0.02) and Daily Living Activities (p=0.03). According to the patients' spontaneous responses, 8 individuals (6 in the PBPC group) believed that their QOL had worsened. Interpretation and Conclusions. With the limitations of a small randomized study, these findings suggest a lower QOL in recipients of allogeneic PBPC than in recipients of BM grafts, probably due to the frequency and severity of chronic graft-versus-host disease. This need to be confirmed in a large international trial. (C) 2002, Ferrata Storti Foundation.
dc.description87
dc.description12
dc.description1281
dc.description1285
dc.languageen
dc.publisherFerrata Storti Foundation
dc.publisherPavia
dc.publisherItália
dc.relationHaematologica
dc.relationHaematologica
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectallogeneic bone marrow transplantation
dc.subjectperipheral blood progenitor cell
dc.subjectquality of life
dc.subjectchronic GVHD
dc.subjectimmunosuppression
dc.subjectStem-cell Transplantation
dc.subjectOf-life
dc.subjectAllogeneic Transplantation
dc.subjectHospital Anxiety
dc.subjectDepression Scale
dc.subjectMalignancies
dc.subjectRecipients
dc.subjectLeukemia
dc.subjectRecovery
dc.subjectTrial
dc.titleQuality of life in patients randomized to receive a bone marrow or a peripheral blood allograft
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución